Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Inks Israeli Distribution Deal for Thyroid Test

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has signed an agreement making Rhenium the exclusive distributor of its RosettaGx Reveal thyroid cancer diagnostic in Israel.

Reveal is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.

According to Rosetta, the exclusivity of the arrangement is based on Rhenium meeting certain volume commitments. The company added that Clalit — the largest of Israel's four health insurance companies — has indicated that it will cover the test.

Additional terms were not disclosed.

"This agreement paves the way for us to partner other diagnostic portfolio products with Rhenium for distribution in Israel in the future," Rosetta President and CEO Kenneth Berlin said in a statement.